Stargardt Disease – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of Stargardt disease (STGD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed lifetime prevalence of Stargardt disease for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for all the countries covered in this report.
Clarivate Epidemiology’s STGD forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of STGD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts Stargardt disease patient populations, as follows:
- Diagnosed incident cases
- Diagnosed incident cases by age
- Diagnosed incident cases by visual acuity
- Diagnosed lifetime prevalent cases
- Diagnosed lifetime prevalent cases by age
- Diagnosed lifetime prevalent cases by visual acuity
Note: Coverage may vary by country.
